Tradestie Institutional Equity Comparison Engine

ICCC vs ACHV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICCC Overall Edge

ICCC Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Growth & Margin, Momentum & Technical while ACHV counters with relative strength in Valuation, Options & Structure. Fundamentally, ICCC trades at N/M Forward P/E with 15.2% operating margin (+11.5% YoY revenue) versus ACHV at 35.3x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ACHV
ICCC N/M vs ACHV 35.3x Fwd P/E
Growth & Margin Winner ICCC
Op Margin 15.2% vs 0.0% ยท YoY +11.5% vs +0.0%
Momentum & Technical Winner ICCC
1Y +88.8% vs +43.0% ยท 52W Pos 91% vs 69%
Options & Structure Winner ACHV
UNCLASSIFIED (N/A IV) vs BREAKOUT (23rd %ile IV)
ICCC NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
1M Return +6.23%
1Y Return +88.76%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
1M Return -8.5%
1Y Return +43.04%
Forward P/E 35.3x
Unified AI Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ICCC +88.76% ACHV +43.04% Spread: +20.9 pp (ICCC Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ICCC TTM Op. Margin: 15.2% ACHV TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICCC vs ACHV. Trailing 12-month operating profitability (ICCC 15.2% vs ACHV 0.0%) and valuation multiples (ICCC N/M vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ICCC (6) vs ACHV (4)
Institutional Metric ICCC ACHV Criterion Row Winner
Market Capitalization Scale $97.7M $692.8M Larger Scale ACHV
Trailing P/E Ratio Valuation 56.6x 35.3x Lower Multiple ACHV
Forward P/E Ratio Valuation N/M 35.3x Lower Multiple ACHV
Revenue Growth (YoY) Growth +11.5% +0.0% Higher Growth ICCC
Operating Margin (TTM) Profitability 15.2% 0.0% Higher Margin ICCC
Net Profit Margin Profitability 2.6% 0.0% Higher Margin ICCC
Return on Equity (ROE) Capital Efficiency 2.6% -845.0% Higher ROE ICCC
52-Week Range Position Momentum 91% ($5โ€“$12) 69% ($3โ€“$9) Stronger Trend ICCC
Beta / 30D Volatility Risk Regime 0.24ฮฒ ยท 46% Vol 1.73ฮฒ ยท 62% Vol Lower Realized Risk ICCC
Unified Institutional Score Composite Signal 43.8 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite ACHV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ICCC vs ACHV Buy Guide
ICCC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICCC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACHV BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live ACHV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ICCC nor ACHV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.